| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.22 | 9e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.096 | 0.06 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.091 | 0.07 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.1 | 0.08 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.067 | 0.2 |